ALKSHealthcare · Drug Manufacturers - Specialty & GenericThe 19 Wall Street analysts covering Alkermes Plc hold a median 12-month price target of $58 — +39.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 6 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Alkermes Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.
Size (19): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ALKS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +39.3% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | Goldman Sachs | Reinstates | Neutral | $50 |
| 22 Sept 2026 | Baird | Maintains | Outperform | $58 → $61 |
| 22 Sept 2026 | RBC Capital | Reiterates | Outperform | $56 |
| 21 Sept 2026 | Needham | Reiterates | Buy | $62 |
| 29 July 2026 | Baird | Maintains | Outperform | $48 → $58 |
| 29 July 2026 | Baird | Maintains | Outperform | — |
| 29 July 2026 | JP Morgan | Maintains | Neutral | — |
| 29 July 2026 | JP Morgan | Maintains | Neutral | $60 → $61 |
| 28 July 2026 | Piper Sandler | Reiterates | Overweight | — |
| 28 July 2026 | Piper Sandler | Reiterates | Overweight | $43 → $65 |
| 20 July 2026 | Stifel | Reiterates | Buy | — |
| 20 July 2026 | Stifel | Reiterates | Buy | $45 → $63 |
| 13 July 2026 | JP Morgan | Reinstates | Neutral | $60 |
| 13 July 2026 | Needham | Maintains | Buy | — |
| 13 July 2026 | Needham | Maintains | Buy | $61 → $62 |
| 2 July 2026 | Mizuho | Maintains | Outperform | — |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | — |
| 29 June 2026 | Wells Fargo | Maintains | Overweight | — |
| 24 June 2026 | Needham | Maintains | Buy | — |
| 22 June 2026 | TD Cowen | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALKS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, Alkermes Plc returned +34.4% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 7% of US stocks
Cheaper than 29% of US stocks
Cheaper than 25% of US stocks
Cheaper than 10% of US stocks
Higher than 76% of US stocks
Higher than 2% of US stocks
Higher than 93% of US stocks
Higher than 73% of US stocks
Higher than 57% of US stocks
Higher than 51% of US stocks
Higher than 72% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alkermes Plc has a market value of $7.0B and an enterprise value of $7.9B.
Revenue in the twelve months to 31 Mar 2026: $1.6B. The latest quarter grew 27.0% year on year.
Net income over the same four quarters: $152.7M, a 9.8% net margin.
Diluted earnings per share, trailing twelve months: $0.90.
Free cash flow in the twelve months to 31 Mar 2026: $221.8M, after $35.0M of capital spending.
Alkermes Plc spent $27.7M on share buybacks in the twelve months to 31 Mar 2026.
Trailing P/E: 109.9×; forward P/E: 23.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alkermes Plc employs 2,050 people — $762K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alkermes Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research published a comparison of biotech stocks LQDA and ALKS, noting that ALKS benefits from a diversified portfolio, its Lumryz product, and a broad pipeline, while LQDA's Yutrepia drives rapid growth.
Why it matters — The piece highlights ALKS's diversification, its Lumryz franchise, and its broader pipeline as relative strengths for investors tracking the company.
Alkermes reported positive Phase 3 results for LUMRYZ, supporting its potential expansion into the idiopathic hypersomnia (IH) indication, which could drive incremental revenue using existing commercial infrastructure and limited SG&A increases. The expansion faces a 10% royalty to Jazz Pharmaceuticals on non-narcolepsy LUMRYZ sales after March 2028.
Why it matters — ALKS watchers would care because LUMRYZ's expansion into idiopathic hypersomnia could become a larger growth and margin driver for the company, leveraging its existing commercial setup while delivering operating leverage.
Alkermes reported positive Phase I data for its investigational ADHD treatment ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
Why it matters — The positive Phase I results mark an early development milestone for ALKS 7290 in Alkermes' pipeline.
Alkermes' stock rose Monday after the company reported the first proof-of-concept for its orexin-modulating drug in adults with ADHD. The result mirrors the approach the company previously used in its narcolepsy program.
Why it matters — This marks a potential new therapeutic application for Alkermes' orexin-modulating platform, expanding its pipeline beyond narcolepsy into the ADHD market.
Alkermes announced positive topline results from a Phase 1 proof-of-concept study of ALKS 7290, its investigational orexin 2 receptor agonist for ADHD. The study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers (n=88) and adults with ADHD (n=5), demonstrating clinical proof-of-concept.
Why it matters — This marks early clinical validation for ALKS 7290, a potential new investigational treatment candidate in Alkermes' pipeline for ADHD.
The 19 Wall Street analysts covering Alkermes Plc have a median 12-month price target of $58, with estimates ranging from $38 to $83. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 analysts covering Alkermes Plc, 14 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Alkermes Plc 61 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Alkermes Plc ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).
No one can know that. What the data says: the median 12-month target from 19 analysts implies +39.3% from the last close, and Ticker Nerd's factor model ranks Alkermes Plc 61 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alkermes Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALKS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $83 over the next 12 months.
Alkermes Plc returned +34.4% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and narcolepsy-related symptoms, with products such as ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ.
The most recent item we track (Zacks Investment Research, 30 Sept 2026): "LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?". Zacks Investment Research published a comparison of biotech stocks LQDA and ALKS, noting that ALKS benefits from a diversified portfolio, its Lumryz product, and a broad pipeline, while LQDA's Yutrepia drives rapid growth.
Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and narcolepsy-related symptoms, with products such as ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ. The company works across research, clinical development, and product commercialization, using its drug formulation and delivery capabilities to support therapies designed for complex and chronic illnesses. Alkermes plc serves patients, healthcare providers, and healthcare systems in the United States, Ireland, and international markets. Founded in 1987 and headquartered in Dublin, Ireland, the company holds a notable position in the neuroscience-focused biopharmaceutical sector.
CEO Mr. Blair C. Jackson · 2,050 employees · Ireland · https://www.alkermes.com
